This is the first large-scale cross-country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first-line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p < 0.001) prognostic factor for risk increase with the hazard ratio between 1.46 and 1.60. Across the three Central European countries, we observed consistent results indicating FCR increased the risk of secondary malignancies in CLL patients. We conclude that secondary malignancies are clearly an undervalued burden for CLL patients, caregivers, and the healthcare system. When evaluating new therapies in regulatory and reimbursement decision making, the factor of secondary malignancies deserves deeper considerations.

1st Department of Internal Medicine Haematology United St István and St László Hospital Budapest Hungary

Department of Hematology Medical University of Lodz Lodz Poland

Experimental Hematooncology Department Medical University of Lublin Lublin Poland

General University Hospital Prague Prague Czech Republic

Institute of Biostatics and Analysis Ltd Brno Czech Republic

Institute of Biostatistics and Analyses of the Faculty of Medicine Brno Czech Republic

Instutute of Hematology and Transfusion Medicine Warsaw Poland

Janssen Cilag Polska Warsaw Poland

Janssen Global Services LLC Budapest Hungary

Medical University of Lublin Department of Clinical Transplantology Medical University of Lublin Lublin Poland

University Hospital Brno and CEITEC Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc23004804

003      

CZ-PrNML

005      

20230425171730.0

007      

ta

008      

230418s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/cam4.5033 $2 doi

035    __

$a (PubMed)36205198

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Kósa, Fruzsina $u Janssen Global Services LLC, Budapest, Hungary $1 https://orcid.org/0000000167709071

245    10

$a Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe / $c F. Kósa, T. Nečasová, M. Špaček, K. Giannopoulos, I. Hus, T. Jurková, E. Koriťáková, M. Chrápavá, M. Nováčková, I. Katinová, D. Krejčí, A. Jujka, Z. Mátrai, I. Vályi-Nagy, T. Robak, M. Doubek

520    9_

$a This is the first large-scale cross-country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first-line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p < 0.001) prognostic factor for risk increase with the hazard ratio between 1.46 and 1.60. Across the three Central European countries, we observed consistent results indicating FCR increased the risk of secondary malignancies in CLL patients. We conclude that secondary malignancies are clearly an undervalued burden for CLL patients, caregivers, and the healthcare system. When evaluating new therapies in regulatory and reimbursement decision making, the factor of secondary malignancies deserves deeper considerations.

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    12

$a chronická lymfatická leukemie $x farmakoterapie $x epidemiologie $7 D015451

650    _2

$a cyklofosfamid $x terapeutické užití $7 D003520

650    _2

$a rituximab $x terapeutické užití $7 D000069283

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971

651    _2

$a Evropa $x epidemiologie $7 D005060

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Nečasová, Tereza $u Institute of Biostatics and Analysis Ltd., Brno, Czech Republic

700    1_

$a Špaček, Martin $u General University Hospital in Prague, Prague, Czech Republic

700    1_

$a Giannopoulos, Krzysztof $u Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland

700    1_

$a Hus, Iwona $u Medical University of Lublin, Department of Clinical Transplantology, Medical University of Lublin, Lublin, Poland $u Instutute of Hematology and Transfusion Medicine, Warsaw, Poland

700    1_

$a Jurková, Tereza $u Institute of Biostatics and Analysis Ltd., Brno, Czech Republic

700    1_

$a Koriťáková, Eva $u Institute of Biostatics and Analysis Ltd., Brno, Czech Republic

700    1_

$a Chrápavá, Marika $u Institute of Biostatics and Analysis Ltd., Brno, Czech Republic

700    1_

$a Nováčková, Martina $u Institute of Biostatics and Analysis Ltd., Brno, Czech Republic

700    1_

$a Katinová, Ivana $u Institute of Biostatistics and Analyses of the Faculty of Medicine, Brno, Czech Republic

700    1_

$a Krejčí, Denisa $u Institute of Biostatistics and Analyses of the Faculty of Medicine, Brno, Czech Republic

700    1_

$a Jujka, Adam $u Janssen-Cilag Polska, Warsaw, Poland

700    1_

$a Mátrai, Zoltán $u 1st Department of Internal Medicine - Haematology, United St István and St László Hospital, Budapest, Hungary

700    1_

$a Vályi-Nagy, István $u 1st Department of Internal Medicine - Haematology, United St István and St László Hospital, Budapest, Hungary

700    1_

$a Robak, Tadeusz $u Department of Hematology, Medical University of Lodz, Lodz, Poland

700    1_

$a Doubek, Michael $u University Hospital Brno and CEITEC Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000212696282

773    0_

$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 12, č. 2 (2023), s. 1961-1971

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36205198 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230418 $b ABA008

991    __

$a 20230425171726 $b ABA008

999    __

$a ok $b bmc $g 1925100 $s 1191013

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 12 $c 2 $d 1961-1971 $e 20221007 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704

LZP    __

$a Pubmed-20230418